View Older Stories View More Recent Stories

Jan 8, 2026 07:00AM Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and He
Jan 8, 2026 06:30AM Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline
Jan 7, 2026 04:53PM Form SCHEDULE 13G Disc Medicine, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 23, 2025 04:01PM Vor Bio adds RA Capital and Forbion partners to board
Dec 23, 2025 04:01PM Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Dec 18, 2025 06:31PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 18, 2025 06:07PM Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 18, 2025 05:23PM Form SCHEDULE 13G Rezolute, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 16, 2025 08:06AM Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1
Dec 15, 2025 07:56PM Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 15, 2025 05:05PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 15, 2025 08:01AM Vor Bio raises $150 million in private placement for drug development
Dec 15, 2025 08:00AM Vor Bio Announces $150 Million Private Placement
Dec 12, 2025 05:14PM Form SCHEDULE 13D Perceptive Capital Solut Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 10, 2025 04:44PM Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 7, 2025 08:00AM CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
Dec 4, 2025 08:00AM Trinity Capital Inc. Provides Equipment Financing to Sortera Technologies to Scale AI-Powered Upcycling Innovation
Dec 3, 2025 04:22PM Form SCHEDULE 13G Benitec Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Dec 3, 2025 08:00AM TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
Nov 21, 2025 05:32PM Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
Nov 20, 2025 10:00AM Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Diseases
Nov 20, 2025 08:30AM Sortera Scales Solution to the Mixed Aluminum Problem with $45 Million in Funding and New Tennessee Facility
Nov 17, 2025 04:44PM Form SCHEDULE 13D Evommune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 17, 2025 04:39PM Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 17, 2025 09:15AM Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
Nov 17, 2025 08:15AM Halda Therapeutics Announces Acquisition by Johnson & Johnson
Nov 17, 2025 08:00AM Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need
Nov 17, 2025 08:00AM T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy
Nov 17, 2025 05:53AM Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
Nov 14, 2025 06:13PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:26PM Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:26PM Form SCHEDULE 13G/A Tourmaline Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:25PM Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:23PM Form SCHEDULE 13G/A RxSight, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:21PM Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:20PM Form SCHEDULE 13G/A Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:18PM Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:17PM Form SCHEDULE 13G/A Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:17PM Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:16PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 14, 2025 04:06PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
Nov 14, 2025 10:23AM LAST CALL: Join Nobel Laureate & Global Leaders to Explore the Next Era of Cell & Gene Therapy in London
Nov 13, 2025 08:47PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 12, 2025 08:27PM Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 12, 2025 04:26PM Form 4 Evommune, Inc. For: Nov 07 Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 10, 2025 04:40PM Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 10, 2025 07:19AM Galecto completes Damora acquisition with $285 million funding round
Nov 10, 2025 07:00AM Galecto Announces Acquisition of Damora Therapeutics
Nov 10, 2025 06:00AM ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
Nov 7, 2025 04:59PM Form SCHEDULE 13D/A Sionna Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
View More Recent Stories View Older Stories